[4-(2H-1,2,3-benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs)

A series of [4-(2H-1,2,3-benzotriazol-2-yl)phenoxy]alkanoic acids has been synthesized and tested as agonists of Peroxisome Proliferator-Activated Receptor (PPAR) a, g, and d. Three compds. displayed 56 to 96% of maximal activity of the ref. drug Wy-14643 on PPARa, and two of these, i.e., 1 and 5, exhibited also moderate activity on either PPARg or d with efficacy equal to 50% and 46% of that of rosiglitazone and GW 501516, resp. Thus, compds. 1 and 5 represent interesting starting point for prepg. novel agents for the treatment of dyslipidemia or of dyslipidemic type-2 diabetes.